Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Immunotherapy in Treating Patients With Stage III-IV Skin Cancer

Research Question:
How does immunotherapy with pembrolizumab work before and after surgery in treating patients with stage III-IV high-risk melanoma (skin cancer)?

Basic Study Information

Purpose:
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.

Location: University of Rochester Medical Center
Study Reference #: CMEL19154

Lead Researcher (Principal Investigator)

Lead Researcher:  Adrienne Victor

Study Contact Information

Study Coordinator: Park Bogan
Phone: (585) 276-4415
Email: Park_Bogan@URMC.Rochester.edu

Additional Study Details

Return to Search